On Wednesday, May 1, The Michael J. Fox Foundation (MJFF) presented a special breaking news edition of its Hot Topics in Parkinson's Disease (PD) Research Seminar Series: “The Future of Trophic Factors,” to address recent disappointing clinical trial results from biotech Ceregene and their therapy CERE-120.

The Webinar was hosted by MJFF Contributing Editor Dave Iverson, and panelists included MJFF Chief Scientific Advisor/neurturin co-discoverer Gene Johnson, PhD, William Marks, MD, of the University of California San Francisco Medical Center, and MJFF Senior Associate Director of Research Programs Jamie Eberling, PhD.

If you didn’t get a chance to log on last week, we encourage you to check it out on demand!

Those interested in learning more about the future of CERE-120, and trophic factor therapies for PD on the whole, can also read this News in Context with Johnson and Eberling, or listen to this conversation between Iverson and Marks. 

You can also register now for our next Hot Topics Webinar, "Biomarkers in PD Research," coming up on Thursday, June 27, from 12–1 p.m. ET. Iverson will lead a discussion with Mark Frasier, PhD, vice president of research programs at MJFF, and Ken Marek, MD, president and senior scientist at the Institute of Neurodegenerative Disorders in New Haven, CT.